Equities

hVIVO PLC

hVIVO PLC

Actions
Health CareHealth Care Providers
  • Price (GBX)22.89
  • Today's Change-0.01 / -0.04%
  • Shares traded88.88k
  • 1 Year change+26.29%
  • Beta1.1116
Data delayed at least 20 minutes, as of Nov 22 2024 08:44 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy2
Outperform3
Hold1
Sell0
Strong Sell0

Share price forecast in GBX

The 6 analysts offering 12 month price targets for hVIVO PLC have a median target of 36.50, with a high estimate of 42.00 and a low estimate of 27.00. The median estimate represents a 59.39% increase from the last price of 22.90.
High83.4%42.00
Med59.4%36.50
Low17.9%27.00

Dividends

In 2023, hVIVO PLC reported a dividend of 0.00 GBP. The 6 analysts covering the company expect dividends of 0.00 GBP for the upcoming fiscal year, maintaining dividends from this year.
Div growth (TTM)--
More ▼

Earnings history & estimates in GBX

hVIVO PLC reported annual 2023 earnings of 1.25 per share on Apr 09, 2024.
Average growth rate+59.79%
More ▼

Revenue history & estimates in GBP

Open Orphan plc had revenues for the full year 2023 of 56.04m. This was 15.61% above the prior year's results.
Average growth rate+157.33%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.